179380-98-4

Upstream product

• 932369-61-4 4-(4-fluorophenyl)-7-methylquinoline-2-carbonitrile 
• 612-60-2 7-methylquinoline 
• 1044278-41-2 7-methylquinoline-2-carbonitrile N-oxide 
• 220143-50-0 7-methylquinoline-2-carbonitrile 
• 4053-43-4 7-methylquinoline N-oxide 
• 1044278-42-3 4-chloro-7-methylquinoline-2-carbonitrile 

Downstream Products

• 1432729-24-2 4-(4-fluorophenyl)-7-(((2S)-2-methyl-(5R)-5-(trifluoromethyl)piperazin-1-yl)methyl)quinoline-2-carboxamide 
• 1432729-25-3 4-(4-fluorophenyl)-7-(((2S)-2-methyl-(5S)-5-(trifluoromethyl)piperazin-1-yl)methyl)quinoline-2-carboxamide 
• 1432730-37-4 4-(4-fluorophenyl)-7-(pyrimidin-5-ylmethyl)quinoline-2-carboxamide 
• 1432728-48-7 4-(4-fluorophenyl)-7-[(3-methyl-2,5-dioxoimidazolidin-1-yl)methyl]quinoline-2-carboxamide 
• 1432731-22-0 7-(bromomethyl)-4-(4-fluorophenyl)quinoline-2-carboxamide 
• 1432728-82-9 7-((1H-benzo[d]imidazol-1-yl)methyl)-4-(4-fluorophenyl)quinoline-2-carboxamide 
• 1432731-27-5 4-(4-fluorophenyl)-7-[(4-formyl-1H-pyrazol-1-yl)methyl]quinoline-2-carboxamide 
• 1432731-28-6 7-({4-[cyclopropyl(hydroxy)methyl]-1H-pyrazol-1-yl}methyl)-4-(4-fluorophenyl)quinoline-2-carboxamide 
• 1432728-85-2 7-{[4-(cyclopropylcarbonyl)-1H-pyrazol-1-yl]methyl}-4-(4-fluorophenyl)quinoline-2-carboxamide 
• 1432728-61-4 4-(4-fluorophenyl)-7-[(3-methyl-2,5-dioxoimidazolidin-1-yl)methyl]quinoline-2-carbonitrile 
• 1432731-24-2 4-(4-fluorophenyl)-7-{[5-(1,1,1-trifluoro-2-hydroxybutan-2-yl)-2H-tetrazol-2-yl]methyl}quinoline-2-carbonitrile 
• 1432731-25-3 4-(4-fluorophenyl)-7-{[5-(1,1,1-trifluoro-2-hydroxybutan-2-yl)-1H-tetrazol-1-yl]methyl}quinoline-2-carbonitrile 
• 1432728-83-0 4-(4-fluorophenyl)-7-{[5-(1,1,1-trifluoro-2-hydroxybutan-2-yl)-2H-tetrazol-2-yl]methyl}quinoline-2-carboxamide 
• 1432728-84-1 C₂₂H₁₈F₄N₆O₂ 

Relevant academic research and scientific papers

QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.